Nurbanu Sezak

Dr. Nurbanu Sezak

Izmir Democracy University, İzmir, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2014 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
ABA. Batirel
A. Batirel
IBI. I. Balkan
I. I. Balkan
OKOguz Karabay
Oguz Karabay
CAC. Agalar
C. Agalar
SAS. Akalin
S. Akalin
HYH. Yilmaz
H. Yilmaz

24 May 2012 in Eurosurveillance
Verified
Journal Article
Open access
HKH Kalaycioglu
H Kalaycioglu
Gulay KorukluogluGulay Korukluoglu
Gulay Korukluoglu
AOA Ozkul
A Ozkul
OOO Oncul
O Oncul
STS Tosun
S Tosun
MEM Ertek
M Ertek
In 2010, 47 human cases of West Nile virus (WNV) infection, including 12 laboratory-confirmed and 35 probable cases, were identified in Turkey. These were the first cases detected during routine surveillance. The patients were from 15 provinces, mainly located in the western part of the country. Incidence was 0.19/100,000 with a maximum of 1.39 in Sakarya province. Forty of the total 47 cases showed neuroinvasive manifestation. Median age was 58 years with a range of four to 86. Ten of the patients died. Enhanced surveillance in humans and animals and mosquito control measures were implemented. The WNV infections were included in the national notifiable diseases list as of April 2011. In 2011, three probable and two confirmed cases of WNV infection were diagnosed in provinces where infections had been detected in the previous year, supporting a lower activity than 2010. However, detection of WNV infections in humans in 2010 and 2011 consecutively, may indicate that WNV has become endemic in the western part of Turkey. Field epidemiological studies were undertaken to understand more about the nature of infection in Turkey.

4 February 2009 in Zoonoses and Public Health
Verified
Journal Article
Closed access
PDF file
NAN. Akkoc
N. Akkoc
ZKZ. Kuruuzum
Z. Kuruuzum
SAS. Akar
S. Akar
AYA. Yuce
A. Yuce
FOF. Onen
F. Onen
NSNurbanu Sezak
Nurbanu Sezak

1 January 2015 in Indian Journal of Pharmacology
Verified
Journal Article
Open access
IBIlkerInanc Balkan
IlkerInanc Balkan
ABAyse Batirel
Ayse Batirel
OKOguz Karabay
Oguz Karabay
CACanan Agalar
Canan Agalar
SASerife Akalin
Serife Akalin
HYHava Yilmaz
Hava Yilmaz
To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp.(MDR-A). Retrospective data of 107 MDR-A BSI cases from 27 tertiary centers in Turkey were included. 14-day mortality. Microbial eradication and clinical improvement. Thirty-six patients in the COL monotherapy (CM) group and 71 in the non-COL based combinations (NCC) group were included in the study. Mean age was 59.98 ± 20 years (range: 18-89) and 50.5% were male. Median duration of follow-up was 40 days (range: 9-297). The 14-day survival rates were 52.8% in CM and 47.23% in NCC group (P = 0.36). Microbiological eradication was achieved in 69% of CM and 83% of NCC group (P = 0.13). Treatment failure was detected in 22.9% of cases in both CM and NCC groups. Univariate analysis revealed that mean age (P = 0.001), Charlson comorbidity index (P = 0.03), duration of hospital stay before MDR-A BSI (P = 0.04), Pitt bacteremia score (P = 0.043) and Acute Physiology and Chronic Health Evaluation II score (P = 0.05) were significant in terms of 14-day mortality. Advanced age (P = 0.01) and duration of hospital stay before MDR-A BSI (P = 0.04) were independently associated with 14-day mortality in multivariate analysis. No significant difference was detected between CM and non-COL based combinations in the treatment of MDR-A BSIs in terms of efficacy and 14-day mortality.

16 December 2011 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
HEHakan Erdem
Hakan Erdem
STSuda Tekin-Koruk
Suda Tekin-Koruk
IKIbrahim Koruk
Ibrahim Koruk
DTDerya Tozlu-Keten
Derya Tozlu-Keten
AUAysegul Ulu-Kılıc
Aysegul Ulu-Kılıc
HLHakan Leblebicioglu
Hakan Leblebicioglu
Background: Training of infectious disease (ID) specialists is structured on classical clinical microbiology training in Turkey and ID specialists work as clinical microbiologists at the same time. Hence, this study aimed to determine the clinical skills and knowledge required by clinical microbiologists. Methods: A cross-sectional study was carried out between June 1, 2010 and September 15, 2010 in 32 ID departments in Turkey. Only patients hospitalized and followed up in the ID departments between January-June 2010 who required consultation with other disciplines were included. Results: A total of 605 patients undergoing 1343 consultations were included, with pulmonology, neurology, cardiology, gastroenterology, nephrology, dermatology, haematology, and endocrinology being the most frequent consultation specialties. The consultation patterns were quite similar and were not affected by either the nature of infections or the critical clinical status of ID patients. Conclusions: The results of our study show that certain internal medicine subdisciplines such as pulmonology, neurology and dermatology appear to be the principal clinical requisites in the training of ID specialists, rather than internal medicine as a whole.

8 October 2015 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
SUSerap Ural
Serap Ural
FKFigen Kaptan
Figen Kaptan
NSNurbanu Sezak
Nurbanu Sezak
SESibel EL
Sibel EL
BÖBahar Örmen
Bahar Örmen
FÇFulya Çakalağaoğlu
Fulya Çakalağaoğlu
Visceral leishmaniasis (VL, kala-azar) is a zoonotic infection caused by Leishmania species which are transmitted to humans by the bites of infected female phlebotomine sandflies. Leishmania infantum is the responsible species of VL in Aegean, Mediterranean, and Central Anatolia regions of Turkey mainly observed sporadically in pediatric age groups. The aim of this study was to evaluate the clinical and laboratory findings of adult patients with VL who were admitted to our hospital. A total of 10 patients (3 female, 7 male; age range: 18-67 years, mean age: 39.3 ± 16.51) followed in the infectious diseases clinic of the hospital between 2000 and 2013 were evaluated retrospectively. The diagnosis of VL was based on the presence of appropriate clinical and physical examination, as well as biochemical findings, positive serological test results (indirect fluorescent antibody test, and rK39 rapid antigen test) and/or detection of amastigote forms of parasite in the bone marrow aspiration samples. Of the cases three were diagnosed with both bone marrow and serology positivity, five with bone marrow positivity and one of each only with liver biopsy and positive serology result. Time interval from onset of the symptoms until the establishment of the specific clinical diagnosis was ranged from 2 to 12 weeks. The most frequent initial symptoms were fever, fatigue and abdominal distension. None of the patients had immunosupressive conditions such as HIV infection, corticosteroid use, immunosupressive treatment, or transplantation. All the patients were from Aegean region and six were living in rural areas. In all cases, hepatosplenomegaly, increased erythrocyte sedimentation rate, albumin/globulin ratio inversion, anemia, leukopenia and among nine cases trombocytopenia were detected. In one case acute renal failure has been developed before treatment and the patient was admitted to dialysis program. Bacterial superinfection occurred in two cases. Patients were treated with either meglumine antimonate (Glucantime(®), 20 mg/kg/day, intramuscularly for 28 days) or liposomal amphotericin B (3 mg/kg/day, intravenously for the first 5 days, then on 14(th) and 21(st) days) according to the availability of drugs. During one year follow-up period all of the patients improved and no recurrence was seen in any patient. In conclusion, among adult patients with fever uncontrolled within 2-week course of ampiric antibiotic treatment without any infectious focus or malignancy, VL should also be considered.